Damora Therapeutics, Inc.

NASDAQ:DMRA

Biotechnology

Healthcare
$22.98 +0.34%

+$0.07 today

Market cap
$1.42B
Beta
1.48
P/E (TTM)
-0.1
EPS (TTM)
-$177.15
52W Low $2.45High $38.33

Volume 0.58M

Average 0.33M

DMRA Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Damora Therapeutics, Inc.NASDAQ: DMRA

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense growth accelerates

Q1 FY2026 income tax expense of $42K rose 2000.0% year over year, ahead of the +109.3% change in trailing-twelve-month income tax expense. Sequentially, it fell 4.5% from the prior quarter.

Context

  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2000.0% holds above the trailing-twelve-month pace of +109.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$42K-4.5% QoQ
Last fiscal yearDec 2025
$50K+22.0% YoY
LTMMar 2026
$90K+109.3% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2000.0%——
1 year+22.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
50K USD
Year-over-year change
+22.0%

Income Tax Expense vs competitors

How DMRA compares with its peers on the latest reported figures

  • DMRA's LTM Mar 2026 income tax expense of $90K is the 5th highest of the 9 companies compared; the peer median is $158.5K.
  • Its year-over-year change of +109.3% is the 2nd highest of 6, against a peer median of -29.4%.
DMRA Competitors Peer median
Income Tax Expense for DMRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$354.98M -9.3%+26.1%6.1%
GMABGenmab A/SLTM Jun 2026$118.01M —-45.5%2.9%
QUREuniQure N.V.LTM Mar 2026$5.62M +147.8%—31.1%
IRONDisc Medicine, Inc.LTM Sep 2026$317K -29.4%——
DMRADamora Therapeutics, Inc.LTM Mar 2026$90K +109.3%——
GERNGeron CorporationLTM Mar 2026$0 ——0.0%
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025-$227K ———
KROSKeros Therapeutics, Inc.LTM Mar 2026-$5.16M -149.9%—15.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$242.26M -25708.8%—80.8%
Peer median (excluding DMRA) $158.5K-29.4%-9.7%10.8%

Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue441K490K830K181K0
Gross Profit(441K)(490K)(830K)(181K)0
Gross Margin—————
Research & Development38.49M48.21M23.77M6.4M201.19M
Selling, General & Admin13.3M12.51M11.86M10.32M9.69M
Operating Expenses51.79M60.72M35.63M16.72M210.87M
Depreciation & Amortization441K490K830K181K34K
EBITDA(51.31M)(61.13M)(37.52M)(21.22M)(209.76M)
EBITDA Margin—————
Operating Income(52.23M)(61.21M)(36.46M)(16.9M)(210.87M)
Operating Margin—————
Interest Income156K722K1.69M844K1.17M
Interest Expense00000
Other Income / Expenses475K(417K)(1.89M)(4.5M)1.08M
Income Before Tax(51.75M)(61.62M)(38.35M)(21.4M)(209.79M)
Pre-Tax Margin—————
Income Tax Expense00041K50K
Net Income(51.75M)(61.62M)(38.35M)(21.44M)(209.84M)
Net Margin—————
EPS (Basic)(51.22)(60.63)(36.08)(18.53)(158.13)
EPS (Diluted)(51.22)(60.63)(36.08)(18.53)(158.13)
Weighted Avg Shares1.01M1.02M1.06M1.16M1.33M
Weighted Avg Shares (Diluted)1.01M1.02M1.06M1.16M1.33M

Damora Therapeutics, Inc.

NASDAQ:DMRA

Intrinsic Alpha fair value

Locked

Current Price

$22.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.